Saturday 17 October 2026
Export LUNG’s income statement to Excel — free account
Pulmonx Corporation
LUNG Healthcare Medical Devices
Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024. In the quarter to June 2026, revenue fell 4.62%, EPS grew 36.8%, free cash flow fell 31.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
1.78
0.07
−3.78%
Follow LUNG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.63 | 0.61 | 0.99 | 0.72 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.59) | (5.35) | (12.69) | (8.13) | |
P/B ratio |
1.41 | 1.18 | 1.66 | 1.10 | |
Price to Tangible BV |
1.50 | 1.24 | 1.74 | 1.15 | |
EV/Sales |
0.42 | 0.33 | 0.63 | 0.29 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.20) | (1.01) | (1.76) | (0.83) | |
EV/FCF |
(1.19) | (1.00) | (1.74) | (0.82) | |
Quick Ratio |
3.35 | 3.84 | 4.09 | 3.96 | |
Current Ratio |
4.32 | 4.91 | 5.07 | 4.86 | |
Net Debt/EBITDA |
2.15 | 1.94 | 3.42 | 2.80 | |
Debt/Assets |
32.62% | 31.02% | 28.61% | 26.85% | |
Debt/Equity |
0.95 | 0.81 | 0.68 | 0.62 | |
Asset Turnover |
0.67 | 0.65 | 0.62 | 0.60 | |
Operating CF/Net income |
0.52 | 0.74 | 0.68 | 0.58 | |
Capex/Depreciation |
0.00 | (0.03) | (0.05) | (0.40) | |
Interest Coverage |
(7.44) | (13.27) | (12.86) | (17.88) | |
Research and Development Expense of Revenue |
22.12% | 23.80% | 20.28% | 22.54% | |
Selling, General and Administrative Expense of Revenue |
95.65% | 117.07% | 101.16% | 119.05% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
16.25% | 20.09% | 18.77% | 24.03% | |
Graham Net Nets |
0.23 | 0.34 | 0.29 | 0.50 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(89.23%) | (100.78%) | (60.18%) | (87.04%) | |
Free Cash Flow Yield |
(55.55%) | (54.42%) | (36.51%) | (49.11%) | |
Revenue per Share |
0.54 | 0.49 | 0.56 | 0.53 | |
Operating CF per Share |
(0.12) | (0.24) | (0.17) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.24) | (0.17) | (0.20) | |
Cash per Share |
1.32 | 1.48 | 1.72 | 1.88 | |
Shareholders Equity per Share |
0.92 | 1.09 | 1.33 | 1.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.92 | 1.09 | 1.33 | 1.47 | |
Free Cash Flow |
(5.21) | (10.11) | (7.10) | (8.25) | |
Working Capital |
67.73 | 73.84 | 81.63 | 88.36 | |
Capital Expenditures |
0.00 | (0.01) | (0.01) | (0.09) | |
Net Current Asset Value |
12.60 | 18.54 | 26.51 | 32.99 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.08 | 12.40 | 12.60 | 12.73 | |
Average Payables |
5.62 | 3.88 | 3.87 | 5.50 | |
Average Inventory |
16.28 | 16.56 | 16.38 | 16.60 | |
Average Assets |
130.96 | 135.35 | 146.07 | 152.84 | |
Average Common Equity |
54.14 | 61.71 | 69.96 | 76.98 |
Columns are period end dates